A 30-day inspection readiness plan is a sponsor planning model, not an FDA deadline. Prioritize participant-risk controls, traceability of pivotal data, unresolved serious findings, and the ability to retrieve records before polishing low-impact materials.
Sponsor timeline and decision checkpoints
Begin with the most consequential control and the evidence needed to resolve it. The following matrix connects each decision to records and an accountable action, rather than treating the list as a generic compliance checkbox.
| Control / question | Evidence to examine | Sponsor action |
|---|---|---|
| Days 1–5: triage | Open findings, inspection scope, key source and TMF inventory | Quality leader ranks issues by impact on safety and data reliability |
| Days 6–10: reconstruct evidence | Source-to-CRF/analysis walkthrough, delegation and safety records | Flag records that cannot be produced or reconciled |
| Days 11–20: remediate | Corrections, CAPA owners, retraining and vendor commitments | Approve actions with documented root cause and effective due dates |
| Days 21–25: simulate | Mock interviews and controlled document request exercise | Measure retrieval and answer quality rather than performance theater |
| Days 26–30: close and brief | Final risk register, evidence packets, leadership escalation | Record residual risk and ownership; do not claim readiness based on calendar alone |
For teams that need support implementing this across functions, BioBoston CRO Mock FDA Inspection can help adapt the controls to the study, vendors, and decision calendar.
Working through the controls
1. Days 1–5: triage
Evidence: Open findings, inspection scope, key source and TMF inventory. Decision: Quality leader ranks issues by impact on safety and data reliability. Record the responsible function and the approved source version, and keep any remaining exceptions visible to the sponsor before this item is closed.
2. Days 6–10: reconstruct evidence
Evidence: Source-to-CRF/analysis walkthrough, delegation and safety records. Decision: Flag records that cannot be produced or reconciled. Record the responsible function and the approved source version, and keep any remaining exceptions visible to the sponsor before this item is closed.
3. Days 11–20: remediate
Evidence: Corrections, CAPA owners, retraining and vendor commitments. Decision: Approve actions with documented root cause and effective due dates. Record the responsible function and the approved source version, and keep any remaining exceptions visible to the sponsor before this item is closed.
4. Days 21–25: simulate
Evidence: Mock interviews and controlled document request exercise. Decision: Measure retrieval and answer quality rather than performance theater. Record the responsible function and the approved source version, and keep any remaining exceptions visible to the sponsor before this item is closed.
5. Days 26–30: close and brief
Evidence: Final risk register, evidence packets, leadership escalation. Decision: Record residual risk and ownership; do not claim readiness based on calendar alone. Record the responsible function and the approved source version, and keep any remaining exceptions visible to the sponsor before this item is closed.
Red flags that should change the plan
- Artificially closing findings with no evidence.
- Losing track of source versions.
- Waiting until a request arrives to test retrieval.
Decision gate and governance
Use an explicit go/no-go readiness meeting: every critical open item needs a risk rationale, named owner, evidence and next action. The control owner should record the decision, evidence version, date, residual uncertainty and next re-review trigger. Where delegated providers perform the work, the sponsor should retain the relevant oversight and acceptance evidence.
Regulatory note: Applicable regulations, trial commitments and agreements must be distinguished from nonbinding FDA and ICH guidance. Apply this framework to the actual product, jurisdiction and study.
Need practical support?
Use BioBoston CRO Mock FDA Inspection to review the evidence, define decision rights, and build a study-specific action plan for the next milestone.
